Transgene Share Price

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris 09:25:00 13/10/2026 pm IST			5-day change	1st Jan Change
0.6930 ^EUR	-0.43%		-4.81%	-27.81%

25/09	Transgene provides update on its operations
08/09	Transgene Expands ProBioGen Partnership With Additional License	MT

Last Transcript: Transgene

Transgene SA - Special Call

29/06

More transcripts

Analysts' recommendations: Transgene

25/06	Oddo BHF Stays Positive on Transgene
07/04	Transgene stands out following licensing agreement with NEC Bio
27/11	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
13/25/13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
18/25/18	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages: Transgene

05/10	Transgene présentera des données précliniques sur PoxSTG-EEV
05/10	Transgene présentera un poster sur les données précliniques de son virus oncolytique innovant au SITC 2026
01/10	Transgene participera à l’Investor Access
25/09	Bourse : les Arnault à la Maison Blanche, HelloFresh avertit et Meta 2000
25/09	Transgene fait le point sur son activité

More news

Managers and Directors: Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	01/06/2023
Lucie Larguier DFI	Director of Finance/CFO	-	27/03/2024
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	02/04/2025

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	27/07/2010
Jean-Luc Bélingard BRD	Director/Board Member	77	19/06/2013
Alain Mérieux BRD	Director/Board Member	88	01/01/2007

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

152

Sector

Biotechnology & Medical Research

Calendar

09/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	€0.6930	-0.43%	49,644
12/26/12	€0.6960	-0.57%	21,638
09/26/09	€0.7000	+2.19%	84,519
08/26/08	€0.6850	-3.11%	1,77,218
07/26/07	€0.7070	-2.88%	88,107

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6930EUR

Average target price

1.100EUR

Spread / Average Target

+58.73%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Transgene

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Transgene

Company calendar

Market Cap	19Cr 21Cr 18Cr 16Cr 30Cr 2.02TCr 30Cr 211.93Cr 83Cr 1.05TCr 80Cr 78Cr 3.37TCr	P/E 2026 *	-4.95x	P/E 2027 *	-3.15x
Enterprise Value	12Cr 14Cr 11Cr 10Cr 19Cr 1.28TCr 19Cr 134.66Cr 53Cr 666.47Cr 51Cr 50Cr 2.14TCr	EV / Sales 2026 *	16.8x	EV / Sales 2027 *	25.3x
Free-Float	19.11%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
OTC Markets	TRGNF	Delayed
Börse Stuttgart	TGNA	Delayed
CBOE	TNGp	Real-time
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Boerse Muenchen	TGNA	Real-time

25/09	Transgene provides update on its operations
08/09	Transgene Expands ProBioGen Partnership With Additional License	MT
03/09	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
02/09	Transgene: no cases of recurrence at three years among patients treated with TG4050
02/09	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
29/06	Transgene SA - Special Call
25/06	Oddo BHF Stays Positive on Transgene
25/06	Positive Preclinical Data for a Transgene Vaccine
25/06	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
22/06	Transgene launches a clinical trial evaluating TG4070 with nivolumab
22/06	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
22/05	Transgene SA Announces Board Appointments	CI

05/10	Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026	GL
01/10	Transgene to Participate in Investor Access	GL
01/10	Transgene to Participate in Investor Access	AQ
24/09	Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field	GL
24/09	2026 Half-Year Financial Report	GL

1 day	-0.43%
1 week	-4.81%
Current month	-4.02%
1 month	-21.34%
3 months	-8.21%
6 months	-10.12%
Current year	-27.81%

Transgene Share Price

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	0.68	0.71
1 month	0.68	0.88
Current year	0.68	1.03
1 year	0.68	1.5
3 years	0.53	1.54
5 years	0.53	2.99
10 years	0.53	3.79

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/12/25	Compagnie Merieux Alliance SAS	Buy	Company	8,47,45,400	63.8367%
02/12/25	Compagnie Merieux Alliance SAS	Buy	Company	3,84,92,172	28.9953%
02/08/24	Compagnie Merieux Alliance SAS	Buy	Company	3,08,98,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-0.43%	-4.81%	-45.86%	-51.20%	21Cr
WUXI APPTEC CO., LTD.	-0.32%	-5.97%	+50.26%	+76.20%	7.06TCr
ARGENX SE	-1.99%	-13.92%	+3.01%	+51.60%	5.12TCr
LONZA GROUP AG	-1.32%	-1.70%	+6.99%	+35.47%	4.8TCr
IQVIA HOLDINGS INC.	-0.58%	+0.27%	+27.93%	+30.76%	4.32TCr
REVOLUTION MEDICINES, INC.	-2.84%	-5.72%	+286.54%	+530.02%	4.16TCr
BEONE MEDICINES AG	-0.38%	-3.78%	+6.74%	+95.25%	3.98TCr
CELLTRION, INC.	-0.39%	-1.59%	+8.69%	+42.99%	3.09TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.66%	-11.49%	+42.12%	+4.38%	2.75TCr
BIONTECH SE	-7.13%	-7.02%	-12.99%	-14.07%	2.41TCr
Average	-1.80%	-4.32%	+37.34%	+80.14%	3.77TCr
Weighted average by Cap.	-1.60%	-4.42%	+49.13%	+100.71%

	2026 *	2027 *
Net sales	72L 80.6L 67.11L 60.84L 1.15Cr 77Cr 1.15Cr 8.04Cr 3.15Cr 40Cr 3.03Cr 2.96Cr 127.68Cr	72L 80.6L 67.11L 60.84L 1.15Cr 77Cr 1.15Cr 8.04Cr 3.15Cr 40Cr 3.03Cr 2.96Cr 127.68Cr
Net income	-3.82Cr -4.28Cr -3.56Cr -3.23Cr -6.08Cr -405.92Cr -6.12Cr -43Cr -17Cr -211.1Cr -16Cr -16Cr -677.42Cr	-6.16Cr -6.9Cr -5.74Cr -5.21Cr -9.8Cr -654.57Cr -9.87Cr -69Cr -27Cr -340.42Cr -26Cr -25Cr -1.09TCr
Net Debt	-6.92Cr -7.75Cr -6.45Cr -5.85Cr -11Cr -735.32Cr -11Cr -77Cr -30Cr -382.42Cr -29Cr -28Cr -1.23TCr	-77L -86.2L -71.77L -65.07L -1.22Cr -82Cr -1.23Cr -8.6Cr -3.37Cr -43Cr -3.24Cr -3.17Cr -136.55Cr